Combating Inflammatory Diseases with a Novel Therapeutic Approach

We are a clinical stage private company focused on developing therapies for inflammatory diseases through a portfolio built around plasma gelsolin (pGSN). pGSN is a naturally occurring human protein that is at the core of a system to regulate the innate immune response, the first line of defense against both infectious and non-infectious health threats.

>40

PATENTS

20+

COLLABORATORS

$50B

MARKET POTENTIAL

OUR MISSION

To address medical issues previously thought to be out of reach -- preventing the damage caused by excess inflammation without suppressing the immune system.

Plasma Gelsolin Addresses Unmet Medical Needs

Inflammation plays a central role in some of the world’s most challenging diseases. Normal levels of plasma gelsolin (pGSN) are rapidly depleted by diverse inflammatory conditions. Restoring gelsolin levels with BioAegis’ proprietary human recombinant form (rhu-pGSN), helps immune cells fight infection and controls inflammation so it does not spread and cause damage. Rhu-pGSN is a non-antibiotic, host-directed, non-immunosuppressive treatment for inflammation due to both infectious and non-infectious causes.

“Plasma gelsolin is thought be an important anti-inflammatory protein… Low levels correlating with mortality could be an important biomarker for disease and may suggest a potential therapeutic role for exogenously administered gelsolin.”

“Inflammation has hit the big time. Over the past decade, it has become widely accepted that inflammation is a driving force behind chronic diseases that will kill nearly all of us. Cancer. Diabetes and obesity. Alzheimer’s disease. Atherosclerosis. Here, inflammation wears a grim mask, shedding its redeeming features and making sick people sicker…..”

“Antimicrobial resistance is an urgent global public health threat, killing at least 1.27 million people worldwide and associated with nearly 5 million deaths in 2019. In the U.S., more than 2.8 million antimicrobial-resistant infections occur each year.”

Creating a Paradigm Shift in Treating Inflammatory Diseases

REGULATES INFLAMMATION

REGULATES INFLAMMATION

A local inflammatory response is essential for the healing process to take place at the site of injury and to fight infection. Plasma gelsolin's unique role is to modulate this necessary inflammatory response so that what was intended to be a mechanism of healing does not become an instrument of morbidity and death.

ACUTE AND CHRONIC DISEASE APPLICATIONS

ACUTE AND CHRONIC DISEASE APPLICATIONS

Multiple disease applications --- $50 billion pipeline market opportunity.  Lead program life-saving host-directed prevention of organ failure in severe pneumonia.

KEY COMPONENT OF INNATE IMMUNITY

KEY COMPONENT OF INNATE IMMUNITY

Plasma Gelsolin is a key component of the innate immune system - the first line of defense against threats to the body. This innate system is not pathogen-specific and reacts equally well to a wide variety of organisms.

FIGHTS INFECTION/NON IMMUNOSUPPRESSIVE

FIGHTS INFECTION/NON IMMUNOSUPPRESIVE

Most agents which interfere with the inflammatory process cause immunosuppression in patients. Plasma gelsolin is unique in that it is not immunosuppressive. Recombinant human plasma gelsolin (rhu-pGSN) improves uptake and killing of gram-positive and negative antibiotic-resistant and sensitive bacterial strains.

BENIGN SAFETY PROFILE

BENIGN SAFETY PROFILE

Recombinant human plasma gelsolin has been manufactured to be identical to the natural human protein. As a result, it is not expected to result in serious side effects when supplementing the depleted protein. In confirmation of this, no serious side effects were identified in animal toxicology studies or four human studies when dosed either intravenously or by inhalation.

EXTENSIVE IP PORTFOLIO

EXTENSIVE IP PORTFOLIO

Our original IP and know-how was licensed from a consortium of Harvard institutions and other collaborators resulting in 40 patents being granted globally to date. Plasma gelsolin will benefit from 12 years of biologics exclusivity in the US beginning at approval of the product and data exclusivity of 11 years in the EU.

A Pipeline Intent on Validating Efficacy for Multiple Indications

This website uses cookies to ensure you get the best experience on our website.
Visit our privacy policy for more information.

This website uses cookies to ensure you get the best experience on our website.
Visit our privacy policy for more information.